Evidence on serious adverse events with GLP-1 agonists remains mixed — some studies report risks including cardiovascular, GI, psychiatric, and thyroid events, while others find no significant associations.
Mixed evidenceacross 22 studies examining serious adverse events with GLP-1 agonists
What the researchers found
Evidence for serious adverse events with GLP-1 agonists is mixed across all categories — anaphylaxis, cardiovascular, GI, psychiatric, and thyroid events have been reported in some studies but not confirmed in others.
Why it matters
With tens of millions of people now using GLP-1 medications, understanding their serious adverse event profile is critical for informed clinical decision-making and patient safety monitoring.
The numbers in context
Literature search from 2010 onward. Covers all reported serious adverse events across the GLP-1 drug class.
How the study worked
Narrative review of 22 articles (5 case reports, 5 RCTs, 9 real-world cohort analyses, 2 meta-analyses, 1 systematic review and meta-analysis) from PubMed, Google Scholar, and Embase from 2010 onwards.
Who was studied
Patients receiving GLP-1 agonists for diabetes or obesity
What this study cannot tell us
Narrative review without systematic methodology or meta-analysis; heterogeneous study designs limit comparison; publication bias may affect reported associations; rapidly evolving literature means some newer safety data may not be captured.
How to read the evidence
Moderate — synthesizes diverse evidence types but without systematic methodology. The mixed findings reflect genuine uncertainty rather than a clear answer.
When this study was published
Published in 2024, reviewing literature from 2010 onwards — timely given the current explosion in GLP-1 prescribing.
The bigger picture
As GLP-1 medications expand from diabetes to obesity and potentially cardiovascular and liver disease, the safety signal question becomes increasingly important. This review highlights the need for longer-term, larger-scale safety surveillance.
Questions still open
- Do different GLP-1 agonists have different safety profiles for serious events?
- Are serious adverse events dose-dependent or related to specific patient populations?
- How does long-term (>5 year) GLP-1 use affect serious event rates?
Common questions
Are GLP-1 medications like semaglutide dangerous?
What serious side effects should I watch for on a GLP-1 medication?
Read the original research
A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment.
Pharmacological reports : PR, 76(5), 981-990
Citation
Tobaiqy, Mansour. (2024). A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment.. Pharmacological reports : PR, 76(5), 981-990. https://doi.org/10.1007/s43440-024-00629-x